{"entity":{"id":"nct07239596","kind":"trial","name":"Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom","aka":[],"tldr":"A phase 1/2 trial of SHR-8068 in renal cell carcinoma, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","summary":"Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom is a phase 1/2 interventional study registered as NCT07239596 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 92 participants planned, started 2026-01-06 and due to reach its primary completion in 2030-12. Interventions recorded: SHR-8068；Adebrelimab ；Bevacizumab, SHR-8068 ; SHR-4610. Conditions listed: Advanced Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07239596","url":"https://clinicaltrials.gov/study/NCT07239596"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["shr-8068"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07239596","phase":"1/2","setting":"An Open, Multicenter Phase Ib/II Clinical Study of SHR-8068 in Combination Anti-tumor Drugs for the Treatment of Advanced Renal Cell Carcinoma","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":92,"outcomes":[]},"route":"/trials/nct07239596/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"shr-8068","kind":"drug","name":"SHR-8068","route":"/drugs/shr-8068/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}